MetaCap

Agios Pharmaceuticals Inc. (AGIO)

NASDAQ: AGIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

31.79+0.07 (+0.22%)

At close: Oct 7, 4:00 PM ET · Delayed 15 min

AGIO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$1.90B
P/E (TTM)
—
Forward P/E
—
EPS (TTM)
-$7.03
Dividend yield
None
Ex-dividend date
—
52-week range
22.24 – 46.00
Day range
31.07 – 32.27
Volume / Avg
1.56M / 1.04M
Beta
—
Shares outstanding
59.70M
Next earnings
Oct 29, 2026

52-week range

$22.24$46.00

AGIO stock today

Shares of Agios Pharmaceuticals (AGIO) finished higher on Oct 7 at $31.79, a gain of 0.22% or $0.07 per share, versus the S&P 500's 0.22% decline. At this level, AGIO sits in the middle of its 52-week range of $22.24 to $46.00: 30.9% below the high, set on Nov 18, 2025 and 42.9% above the low. AGIO is up 16.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 22.2%.

Agios Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$7.03), so its P/E ratio is not meaningful. Agios Pharmaceuticals's next earnings report is expected on Oct 29, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About Agios Pharmaceuticals

Company profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Brian M. Goff M.B.A.
Headquarters
Cambridge, MA
Employees
539
IPO year
2013
Website
agios.com

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$46.00+44.70%

  • Strong buy 0
  • Buy 7
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $32.00High $73.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Oct 29, 2026
EPS estimate
$-1.32

AGIO news

All AGIO news

Agios Pharmaceuticals peers

Health Care sector
AGIO peer companies
CompanyPrice% ChgMarket capCompare
GPCRStructure Therapeutics Inc. ADR26.68-2.88%$1.90Bvs AGIO
ZYMEZymeworks Inc.26.53+3.43%$1.90Bvs AGIO
PVLAPalvella Therapeutics Inc.130.59+2.02%$1.88Bvs AGIO
TRVITrevi Therapeutics Inc.13.14-0.30%$1.87Bvs AGIO
ADRXADARx Pharmaceuticals Inc.17.33-6.73%$1.85Bvs AGIO
SRPTSarepta Therapeutics Inc.17.50+1.10%$1.85Bvs AGIO
XERSXeris Biopharma Holdings Inc.10.11+0.40%$1.84Bvs AGIO
ZBIOZenas BioPharma Inc.28.18+4.60%$1.84Bvs AGIO

Indexes, lists and sector

Agios Pharmaceuticals stock FAQ

What is Agios Pharmaceuticals's stock price today?

AGIO last traded at $31.79 as of Oct 7, 4:00 PM EDT, up 0.22% on the day. Prices are delayed at least 15 minutes.

When is Agios Pharmaceuticals's next earnings date?

Agios Pharmaceuticals is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $-1.32.

Who is Agios Pharmaceuticals's CEO?

Mr. Brian M. Goff M.B.A. is the chief executive officer of Agios Pharmaceuticals Inc., which has about 539 employees.

What is the AGIO 52-week high?

The 52-week high for AGIO is $46.00 and the 52-week low is $22.24. The stock is currently 30.9% below its high.

Compare AGIO